Newsletter
Marksans Pharma is acquiring Netherlands-based pharmaceutical company QliniQ BV for €7.5 million (around ₹74 crore) as it looks to strengthen its presence in Europe.
QliniQ sells niche pharmaceutical products and medical devices across women's health, dermatology, and respiratory care.
Why this matters: until now, the company largely manufactured medicines and sold them through partners. With this acquisition, the company gets direct access to customers in Europe. That means better control over pricing, distribution, and product launches, while also capturing a larger share of profits.
QliniQ generated €9.35 million in revenue and €1 million in profit in 2025. The company has also been growing rapidly, with revenue rising at nearly 41% annually over the last three years, while remaining debt-free.
The bigger picture: Indian pharma companies are increasingly moving beyond manufacturing and focusing on owning distribution channels in developed markets. Europe remains one of the world's largest regulated pharmaceutical markets, where direct market access can create long-term growth opportunities.
For Marksans, the deal is less about buying a large company and more about securing a ready-made platform to sell more products across Europe in the years ahead.
